NEW YORK (GenomeWeb News) – Proteros Biostructures today said that it has entered into a drug discovery services agreement with the CHDI Foundation, a non-profit scientific organization focused on discovering and developing Huntington's disease therapies.
Under the alliance, Martinsried, Germany-based Proteros will provide structure-based drug discovery services to CHDI using its integrated discovery platform including proprietary X-ray crystallography tools.
Further details of the agreement were not disclosed.